Experimental drug targets Hard-to-Treat lung cancer

NCT ID NCT04982224

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called REGN5093-M114, alone or with another drug, in people with advanced non-small cell lung cancer that has too much MET protein. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early, but the results help researchers understand how to treat this type of cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NSCLC

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Henry Ford Hospital, Henry Ford Cancer Institute

Detroit, Michigan, 48202, United States
Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building

Baltimore, Maryland, 21231, United States
MUSC Hollings Cancer Center

Charleston, South Carolina, 29425, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Next Virginia

Fairfax, Virginia, 22031, United States
Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building

Baltimore, Maryland, 21231, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of California Irvine School of Medicine - Suite 400, Room 407

Orange, California, 92868, United States
University of Colorado Hospital Anshutz Outpatient Pavillion

Denver, Colorado, 80045, United States
University of Pittsburgh Medical Center - Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.